VNA 318
Alternative Names: VNA-318Latest Information Update: 23 Aug 2024
At a glance
- Originator Vandria
- Class Nootropics; Small molecules
- Mechanism of Action Autophagy stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cognition disorders
Most Recent Events
- 21 Aug 2024 Vandria plans a phase I single ascending dose (SAD) and multiple ascending dose (MAD) first-in-man trial for Cognition-disorders in 2025
- 21 Aug 2024 Vandria plans a three parallel phase Ia/IIb efficacy studies in 2025
- 14 Dec 2023 Vandria plans a clinical trial for VNA 318 in Europe in Q2 2024